CRIS Current Research Information System

MARINELLI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.848
EU - Europa 1.185
AS - Asia 1.152
AF - Africa 126
SA - Sud America 67
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 1
Totale 4.395
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.829
SG - Singapore 386
VN - Vietnam 303
CN - Cina 256
GB - Regno Unito 234
IT - Italia 234
SE - Svezia 190
DE - Germania 163
HK - Hong Kong 89
IN - India 60
NL - Olanda 59
RU - Federazione Russa 56
IE - Irlanda 50
BR - Brasile 46
FR - Francia 43
TG - Togo 35
UA - Ucraina 33
SC - Seychelles 31
ZA - Sudafrica 27
FI - Finlandia 26
CH - Svizzera 23
EE - Estonia 17
BG - Bulgaria 16
CA - Canada 15
CI - Costa d'Avorio 15
EU - Europa 15
JO - Giordania 13
JP - Giappone 12
AT - Austria 10
BE - Belgio 10
KR - Corea 9
NG - Nigeria 9
AR - Argentina 7
ID - Indonesia 7
ES - Italia 6
PL - Polonia 6
CL - Cile 5
CO - Colombia 4
LT - Lituania 4
MX - Messico 4
MY - Malesia 3
BD - Bangladesh 2
GH - Ghana 2
HR - Croazia 2
IQ - Iraq 2
MA - Marocco 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
SN - Senegal 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DZ - Algeria 1
EC - Ecuador 1
GR - Grecia 1
KE - Kenya 1
LB - Libano 1
MK - Macedonia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PH - Filippine 1
TR - Turchia 1
TW - Taiwan 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.395
Salva come PNG Salva come JPEG
Città #
Singapore 270
Ashburn 222
Dong Ket 217
Southend 214
Fairfield 209
Chandler 185
Seattle 99
Wilmington 91
Hong Kong 89
Woodbridge 87
Houston 79
Santa Clara 61
Bologna 60
Princeton 56
Cambridge 54
Ann Arbor 50
Dublin 50
Boardman 39
Lomé 35
Beijing 34
Los Angeles 29
Dallas 27
Ho Chi Minh City 26
Padova 24
Hanoi 22
Westminster 22
Dearborn 21
Berlin 20
Bern 20
Nanjing 20
New York 20
Hefei 18
Helsinki 18
Jinan 18
Sofia 16
Abidjan 15
Munich 15
Frankfurt am Main 14
Amman 13
Saint Petersburg 13
Turin 13
Chicago 11
Jacksonville 11
Nanchang 11
Redondo Beach 11
Brussels 10
Düsseldorf 10
Tokyo 10
Abeokuta 9
Amsterdam 9
Buffalo 9
Changsha 9
Phoenix 9
Seoul 9
San Diego 8
Milan 7
Toronto 7
Bühl 6
Catanzaro 6
Hebei 6
Medford 6
Shenyang 6
Bremen 5
Des Moines 5
Falkenstein 5
Jakarta 5
Nuremberg 5
Olalla 5
Redwood City 5
Sassari 5
Turku 5
Vienna 5
Zhengzhou 5
Florence 4
Guangzhou 4
Kunming 4
Montreal 4
Ningbo 4
Rio de Janeiro 4
Rome 4
Shenzhen 4
Tianjin 4
Agawam 3
Atlanta 3
Bari 3
Brooklyn 3
Denver 3
Elk Grove Village 3
Hyderabad 3
Johannesburg 3
Lanzhou 3
Lappeenranta 3
London 3
Madrid 3
Moscow 3
Mountain View 3
Mülheim 3
Orem 3
Prineville 3
Redmond 3
Totale 2.930
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 240
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 221
Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: experience of the Bologna Liver Oncology Group. 218
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma 213
Platelet count does not predict bleeding in cirrhotic patients: Results from the PRO-LIVER Study 201
Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma 184
Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. 184
Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? 183
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 180
null 164
Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry 164
Clinical and economical impact of 2010 AASLD guidelines for the diagnosis of hepatocellular carcinoma 157
Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: A multicenter real-life study 156
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 155
Early Prediction of Treatment Response to Sorafenib with Elastosonography in a Mice Xenograft Model of Hepatocellular Carcinoma: A Proof-of-Concept Study. 147
Patterns of appearance and risk of misdiagnosis of intrahepatic cholangiocarcinoma in cirrhosis at contrast enhanced ultrasound. 147
Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients 145
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study 134
The role of ultrasound elastographic techniques in chronic liver disease: current status and future perspectives 132
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 121
Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases. 117
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. 107
Experience with regorafenib in the treatment of hepatocellular carcinoma 106
Letter to the editor. 105
Ipertensione portale. 105
Erratum to: Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry (Intern Emerg Med, 10.1007/s11739-016-1416-8) 104
The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: A retrospective multicentre study. 102
null 77
Sorafenib versus Y90 radioembolization in cirrhotic patients with hepatocellular carcinoma (HCC): cohort and nested control-case study with propensity analysis 74
Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib 61
Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC 56
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 16
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 16
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 7
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 6
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 4
Totale 4.509
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.858
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.858
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021362 0 0 0 0 0 11 11 16 44 24 16 240
2021/2022612 61 14 24 62 51 33 12 32 18 44 181 80
2022/2023669 79 105 27 94 35 68 16 26 114 14 46 45
2023/2024194 24 25 12 20 15 47 11 4 13 13 6 4
2024/2025629 23 70 73 61 97 32 41 27 10 64 20 111
2025/2026940 164 133 137 135 244 127 0 0 0 0 0 0
Totale 4.509